Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 233

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Study of Navtemadlin for Patients with Myelofibrosis Resistant to JAK Inhibitors

Study of BDC-1001 and Nivolumab for Patients with Advanced HER2-Positive Solid Tumors

Study of BDC-1001 and Nivolumab for Patients with Advanced HER2-Positive Solid Tumors

Study of Monalizumab and Volrustomig for Patients with MSI and/or dMMR Metastatic Cancer

Study of Monalizumab and Volrustomig for Patients with MSI and/or dMMR Metastatic Cancer

Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer

Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer

Study on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy

Study on Dacarbazine, Pembrolizumab, Nivolumab, and Ipilimumab for Patients with Unresectable or Metastatic Melanoma Resistant to Immunotherapy

Study of drug interactions between enzalutamide, morphine and edoxaban in patients with prostate cancer

Study of drug interactions between enzalutamide, morphine and edoxaban in patients with prostate cancer

Study on Sentinel Lymph Node Mapping Using Gallium-68 Chloride and Tilmanocept in Patients with High-Risk Endometrial Cancer

Study on Sentinel Lymph Node Mapping Using Gallium-68 Chloride and Tilmanocept in Patients with High-Risk Endometrial Cancer

Study of Trifluridine and Tipiracil in Patients with ER-Positive, HER2-Negative Advanced Breast Cancer After Chemotherapy

Study of Trifluridine and Tipiracil in Patients with ER-Positive, HER2-Negative Advanced Breast Cancer After Chemotherapy

Study of L19IL2 and L19TNF for Patients with Advanced Basal Cell Carcinoma or Cutaneous Squamous Cell Carcinoma Not Eligible for Surgery or Radiation

Study of L19IL2 and L19TNF for Patients with Advanced Basal Cell Carcinoma or Cutaneous Squamous Cell Carcinoma Not Eligible for Surgery or Radiation

Study on the Safety of Low-Dose Cytarabine or Azacitidine with Venetoclax and Quizartinib for Acute Myeloid Leukemia in Patients Aged 60+ Ineligible for Standard Chemotherapy

Study on Bevacizumab and Erlotinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation

Study on Bevacizumab and Erlotinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation

Study of Atezolizumab with High Dose Radiation vs. Radiation Alone for Patients with Oligometastatic Soft Tissue Sarcoma

Study of Atezolizumab with High Dose Radiation vs. Radiation Alone for Patients with Oligometastatic Soft Tissue Sarcoma